Xgeva FDA Approval History
FDA Approved: Yes (First approved November 18, 2010)
Brand name: Xgeva
Generic name: denosumab
Dosage form: Injection
Company: Amgen Inc.
Treatment for: Osteolytic Bone Metastases of Solid Tumors, Osteolytic Bone Lesions of Multiple Myeloma, Giant Cell Tumor of Bone, Hypercalcemia of Malignancy
Xgeva (denosumab) is a RANK ligand (RANKL) inhibitor indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. Xgeva is also indicated for treatment giant cell tumor of bone and for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.
Development timeline for Xgeva
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
